<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph" /><meta name="keywords" content="Certolizumab pegol; Cimzia; Certolizumab pegol" /><meta name="IX" content="Cimzia; Certolizumab pegol" /><meta name="IXM" content="Certolizumab pegol" /><title>CERTOLIZUMAB PEGOL: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="204103.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="204103.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=204103.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2077.htm">10 Musculoskeletal and joint diseases</a> &gt; <a href="5182.htm">10.1 Drugs used in rheumatic diseases and gout</a> &gt; <a href="5288.htm">10.1.3 Drugs that suppress the rheumatic disease process</a> &gt; <a href="202659.htm">Cytokine modulators</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="217729.htm" title="Previous: BELIMUMAB">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="204105.htm#_204105" title="Next: Cimzia®">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a308034.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Certolizumab Pegol</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Miscellaneous Therapeutic Agents 92:00 &gt; Disease-modifying Antirheumatic Drugs 92:36</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/20674-t.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Certolizumab pegol</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: C &gt; Interactions of Certolizumab pegol</p></div></li></ul><ul><li><h3>British National Formulary (2)</h3></li><li><a href="202659.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Cytokine modulators</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 10 Musculoskeletal and joint diseases &gt; 10.1 Drugs used in rheumatic diseases and gout &gt; 10.1.3 Drugs that suppress the rheumatic disease process</p></div></li><li><a href="204105.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Cimzia®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 10 Musculoskeletal and joint diseases &gt; 10.1 Drugs used in rheumatic diseases and gout &gt; 10.1.3 Drugs that suppress the rheumatic disease process &gt; Cytokine modulators &gt; CERTOLIZUMAB PEGOL</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/20674-t.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Certolizumab Pegol</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Gastrointestinal Drugs &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/02003.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Certolizumab Pegol</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; C &gt; CE</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E2E0E10E3E0R0D2265.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Certolizumab pegol</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; C</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1 id="_204103">CERTOLIZUMAB PEGOL</h1><?highlighter on?><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i1160.htm" title="Go to appendix 1">Certolizumab pegol</a>).</div><div class="cAF"><h2>Indications</h2> <p class="cAF">see under <a title="BNF:target-block: certolizumab pegol" href="202659.htm#_204104">Cytokine Modulators</a> above</p></div><div class="cAF"><h2>Cautions</h2> <p class="cAF">predisposition to infection; monitor for infection before, during, and for 5 months
after treatment (see also Tuberculosis below); do not initiate until active infections are controlled; discontinue if new serious infection develops until
infection controlled; hepatitis B virus—monitor
for active infection; mild heart failure
(discontinue if symptoms develop or worsen—avoid in moderate to severe heart failure); demyelinating
CNS disorders (risk of exacerbation); history or development
of malignancy; <b>interactions</b>: Appendix 1 (certolizumab
pegol)</p><div class="cAV"><h3>Tuberculosis</h3> <p class="cAX">Patients should be evaluated
for tuberculosis before treatment. Active tuberculosis
should be treated with standard treatment (<a title="BNF:sub-section: Antituberculosis drugs" href="3899.htm#_3899">section 5.1.9</a>) for at least 2 months before
starting certolizumab pegol. Patients who have previously
received adequate treatment for tuberculosis can start certolizumab
pegol but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were
previously not treated adequately, chemoprophylaxis should ideally
be completed before starting certolizumab pegol. In patients at high risk of tuberculosis who cannot be assessed by
tuberculin skin test, chemoprophylaxis can be given concurrently with
certolizumab pegol. Patients should be
advised to seek medical attention if symptoms suggestive of tuberculosis
(e.g. persistent cough, weight loss, and fever) develop</p></div><div class="cAV"><h3>Blood disorders</h3> <p class="cAX">Patients should be
advised to seek medical attention if symptoms suggestive of blood
disorders (such as fever, sore throat, bruising, or bleeding) develop</p></div></div><div class="cAF"><h2>Contra-indications</h2> <p class="cAF">severe active infection (see also Cautions)</p></div><div class="cAF"><h2>Pregnancy</h2> <p class="cAF">avoid; manufacturer advises adequate contraception
during treatment and for at least 5 months after last dose</p></div><div class="cAF"><h2>Breast-feeding</h2> <p class="cAF">manufacturer advises use only if potential benefit
outweighs risk—no information available</p></div><div class="cAF"><h2>Side-effects</h2> <p class="cAF">see under <a title="BNF:target-block: Cytokine inhibitor side-effects notes 10.1.3" href="202659.htm#_200785">Cytokine Modulators</a> and Cautions above; hypertension; sensory abnormalities; rash; <i>less commonly</i> ascites, cholestasis, gastro-intestinal disorders
(including perforation and ulcer), hepatic disorders, appetite disorders;
cardiomyopathies (including heart failure), dyslipidaemia, syncope,
oedema, dizziness, ischaemic coronary artery disorders, arrhythmias;
asthma, pleural effusion, cough; peripheral neuropathy, tremor, anxiety,
mood disorders; influenza-like illness; menstrual disorders, renal
impairment, haematuria; malignancy (including solid tumours, lymphoma,
and leukaemia), skin cancer, benign tumours; haemorrhage, electrolyte
disorders; muscle disorders; visual disturbance, ocular inflammation;
ecchymosis, impaired healing, alopecia, photosensitivity, acne, skin
discoloration, nail disorders, new onset or worsening psoriasis, dermatitis; <i>rarely</i> cholelithiasis, splenomegaly, atrioventricular block,
cerebrovascular accident, Raynaud’s phenomenon, interstitial lung
disease, impaired coordination, trigeminal neuralgia, seizures, thyroid disorders, sexual dysfunction, nephropathy, tinnitus; <i>also reported</i> multiple sclerosis</p></div><div class="cAF"><h2>Dose</h2> <p class="cR"><span class="cU">By subcutaneous injection</span>, <span class="cAK">adult</span> over 18 years, 400 mg, repeated 2 weeks and
4 weeks after initial injection, then 200 mg every 2 weeks; review
treatment if no response within 12 weeks</p></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="204105.htm#_204105" title="Cimzia®">Cimzia®</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="217729.htm">Previous: BELIMUMAB</a> | <a class="top" href="204103.htm#">Top</a> | <a accesskey="]" href="204105.htm#_204105" title="Cimzia®">Next: Cimzia®</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>